Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-masked, Randomized, Multicenter, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of GAL-101, 2%, Ophthalmic Solution in Patients With Non-foveal Geographic Atrophy Secondary to Non-neovascular Age-related Macular Degeneration: eDREAM Study

NCT06659549 is registered in ClinicalTrials.gov with Galimedix Therapeutics Inc as lead sponsor.

NCT NCT06659549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06659549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-masked, Randomized, Multicenter, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of GAL-101, 2%, Ophthalmic Solution in Patients With Non-foveal Geographic Atrophy Secondary to Non-neovascular Age-related Macular Degeneration: eDREAM Study
Lead sponsor
Galimedix Therapeutics Inc
Phase
Phase 2
Overall status
Recruiting
Start date
January 10, 2025
Completion date
May 30, 2027
Enrollment
110 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy of the macula